Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHCY | P23526 | 7/20 | 0.79 |
| ▸ | NADK | O95544 | 1/20 | 0.79 |
| ▸ | DOT1L | Q8TEK3 | 3/20 | 0.78 |
| ▸ | DNMT3B | Q9UBC3 | 2/20 | 0.78 |
| ▸ | PNMT | P11086 | 1/20 | 0.78 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.78 |
| ▸ | PRMT7 | Q9NVM4 | 2/20 | 0.76 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.72 |
| ▸ | DPP4 | P27487 | 1/20 | 0.71 |
| ▸ | MEN1 | O00255 | 1/20 | 0.71 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.71 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.71 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.71 |
| ▸ | GAPDH | P04406 | 1/20 | 0.71 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.71 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.71 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.71 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.71 |
| ▸ | STAT6 | P42226 | 1/20 | 0.71 |
| ▸ | PI4KA | P42356 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL998091 | 1.00 | AHCY (0.79) | AHCYNADKDOT1LDNMT3BPNMT | |
| SCHEMBL2829515 | 0.91 | DOT1L (0.82) | AHCYNADKDOT1LDNMT3BPNMT | |
| SCHEMBL2829520 | 0.91 | DOT1L (0.82) | AHCYNADKDOT1LDNMT3BPNMT | |
| SCHEMBL21243035 | 0.90 | DOT1L (0.84) | AHCYNADKDOT1LDNMT3BPNMT | |
| SCHEMBL6897966 | 0.89 | DOT1L (0.83) | AHCYNADKDOT1LDNMT3BPNMT | |
| SCHEMBL30216716 | 0.89 | DOT1L (0.83) | AHCYNADKDOT1LDNMT3BPNMT | |
| Methylthioadenosine SCHEMBL890628 | 0.89 | AHCY (0.83) | AHCYNADKDOT1LDNMT3BPNMT | |
| Methylthioadenosine SCHEMBL20798030 | 0.89 | AHCY (0.83) | AHCYNADKDOT1LDNMT3BPNMT | |
| Methylthioadenosine SCHEMBL11954365 | 0.89 | AHCY (0.83) | AHCYNADKDOT1LDNMT3BPNMT | |
| Methylthioadenosine SCHEMBL10013421 | 0.89 | AHCY (0.83) | AHCYNADKDOT1LDNMT3BPNMT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150119351-A1 | THERAPY OF TUMORS AND INFECTIOUS AGENTS DEFICIENT IN METHYLTHIOADENOSINE PHOSPHORYLASE | LUBIN ADAM (US) | 2015-04-30 | — | — | US | claimed |
| US-8796241-B2 | Therapy of tumors and infectious agents deficient in methylthioadenosine phosphorylase | LUBIN ADAM (US) | 2014-08-05 | — | — | US | claimed |
| US-20120094947-A1 | METHOD FOR THE SELECTIVE THERAPY OF DISEASE | LUBIN ADAM (US) | 2012-04-19 | — | — | US | claimed |
| EP-0693127-A1 | USE OF TOMATO E8-DERIVED PROMOTERS TO EXPRESS HETEROLOGOUS GENES, E.G. S-ADENOSYLMETHIONINE HYDROLASE, IN RIPENING FRUIT | EPITOPE, INC. (US) | 1996-01-24 | — | — | EP | claimed |
| WO-1994024294-A1 | USE OF TOMATO E8-DERIVED PROMOTERS TO EXPRESS HETEROLOGOUS GENES, E.G. S-ADENOSYLMETHIONINE HYDROLASE, IN RIPENING FRUIT | EPITOPE, INC. (US) | 1994-10-27 | — | — | WO | claimed |
| US-20150119351-A1 | THERAPY OF TUMORS AND INFECTIOUS AGENTS DEFICIENT IN METHYLTHIOADENOSINE PHOSPHORYLASE | LUBIN ADAM (US) | 2015-04-30 | — | — | US | disclosed |
| US-8796241-B2 | Therapy of tumors and infectious agents deficient in methylthioadenosine phosphorylase | LUBIN ADAM (US) | 2014-08-05 | — | — | US | disclosed |
| US-20120094947-A1 | METHOD FOR THE SELECTIVE THERAPY OF DISEASE | LUBIN ADAM (US) | 2012-04-19 | — | — | US | disclosed |
| EP-1874790-B1 | NEW S-ADENOSYL-L-METHIONINE ANALOGS WITH EXTENDED ACTIVATED GROUPS FOR TRANSFER BY METHYLTRANSFERASES | RWTH AACHEN (DE) | 2010-08-18 | — | — | EP | disclosed |
| EP-2192905-A2 | METHOD FOR THE SELECTIVE THERAPY OF DISEASE | Lubin, Adam (US) | 2010-06-09 | — | — | EP | disclosed |
| WO-2009032057-A2 | METHOD FOR THE SELECTIVE THERAPY OF DISEASE | LUBIN ADAM (US) | 2009-03-12 | — | — | WO | disclosed |
| EP-1874790-A2 | NEW S-ADENOSYL-L-METHIONINE ANALOGS WITH EXTENDED ACTIVATED GROUPS FOR TRANSFER BY METHYLTRANSFERASES | RWTH Aachen (DE) | 2008-01-09 | — | — | EP | disclosed |
| EP-1482977-A1 | COMBINATION THERAPIES FOR TREATING METHYLTHIOADENOSINE PHOSPHORYLASE DEFICIENT CELLS | PFIZER INC. (US) | 2004-12-08 | — | — | EP | disclosed |
| US-20040043959-A1 | Combination therapies for treating methylthioadenosine phosphorylase deficient cells | AGOURON PHARMACEUTICALS INC. | 2004-03-04 | — | — | US | disclosed |
| WO-2003074083-A1 | COMBINATION THERAPIES FOR TREATING METHYLTHIOADENOSINE PHOSPHORYLASE DEFICIENT CELLS | PFIZER INC. (US) | 2003-09-12 | — | — | WO | disclosed |
| EP-0233031-B1 | METHYLTHIORIBOSE ANALOGUES, THEIR PREPARATION AND USE AS MEDICINAL AGENTS AND BIOCIDES | STATE OF OREGON BY AND THROUGH OREGON STATE BOARD OF HIGHER EDUCATION ON BEHALF OREGON HEALTH SC. UNIV. AND OREGON STATE UNIV. (US) | 1993-04-07 | — | — | EP | disclosed |
| US-4820692-A | PARASITICIDES, FUNGICIDES | STATE OF OREGON, ACTING BY AND THROUGH THE OREGON STATE BOARD OF HIGHER EDUCATION, ACTING FOR AND ON BEHALF OF THE OREGON HEALTH SCIENCES UNIVERSITY AND OREGON STATE UNIVERSITY (US) | 1989-04-11 | — | — | US | disclosed |
| EP-0233031-A2 | Methylthioribose analogues, their preparation and use as medicinal agents and biocides | STATE OF OREGON BY AND THROUGH OREGON STATE BOARD OF HIGHER EDUCATION ON BEHALF OREGON HEALTH SC. UNIV. AND OREGON STATE UNIV. (US) | 1987-08-19 | — | — | EP | disclosed |
| US-4454122-A | ALSO ANTIPYRETICS, ANTICOAGULANTS | BIORESEARCH S.R.L. (IT) | 1984-06-12 | — | — | US | disclosed |
| US-4373097-A | Process for preparing adenosine derivatives of anti-inflammatory and analgesic activity | BIORESEARCH S.R.L. (IT) | 1983-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040043959-A1 | Combination therapies for treating methylthioadenosine phosphorylase deficient cells | APRT, MTAP, TYMP | AHCY 62/4885NADK 1514/4885DOT1L 1250/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.